NGS-based classifier combined with WBC and MRD identifies an adverse group of patients with T-ALL. (A) CIR in 332 patients with T-ALL by NGS-based classifier combined with WBC and MRD. The 5-year CIR in 332 patients with T-ALL was 12% (95% CI, 6-19) in CR1-FAV patients, 26% (95% CI, 19-33) in CR1-INT patients (P = .005, compared with CR1-FAV), and 51% (95% CI, 39-61) in CR1-ADV patients (P < .0001, compared with CR1-INT). (B) At 5 years, OS was 93% (95% CI, 88-98) in CR1-FAV patients, 81% (95% CI, 75-88) in CR1-INT patients (P = .0008, compared with CR1-FAV), and 53% (95% CI, 43-66) in CR1-ADV patients (P < .0001, compared with CR1-INT).